ReviewSupportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer2015
Burden of skeletal-related events in prostate cancer: unmet need in pain improvement.
Review in Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 1 synthesis or guideline pooled it, 61 citations in OpenAlex.
- A Systematic Review of the Economic Burden of Prostate Cancer: Direct and Indirect Cost Perspectives.PharmacoEconomics · 2026Pooled it
- Interprovider Variation in Initiation of Bone-Modifying Agents for Patients With Prostate Cancer.JCO oncology practice · 2026Observational
- Bone health in advanced prostate cancer: pathophysiology and management strategies.The oncologist · 2026Review
- Article
- Questionable indication for postoperative radiotherapy after surgery for metastases of the major long bones: A single-centre cohort study of 552 fractures/526 patients.Journal of bone oncology · 2026Article
- Real-world impact of acupuncture on analgesics and healthcare resource utilization in breast cancer survivors with pain.BMC medicine · 2024Article
- Costs to Medicare of Nonrecommended Bone-Modifying Agent Use for Castration-Sensitive Prostate Cancer.JCO oncology practice · 2024Article
- Physician knowledge, practice patterns, and barriers encountered regarding guideline-concordant use of bone modifying agents for prostate cancer.The Prostate · 2024Article
- A Case of Success: Complete Response to Radium-223 in Metastatic Castration-Resistant Prostate Cancer.Cureus · 2024Article
- Pain Outcomes in Patients with Metastatic Castration-Resistant Prostate Cancer Treated withJournal of nuclear medicine : official publication, Society of Nuclear Medicine · 2023Observational
- Supportive care interventions for men with urological cancers: a scoping review.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2023Article
- Article
- Improving Bone Health in Patients with Metastatic Prostate Cancer with the Use of Algorithm-Based Clinical Practice Tool.Geriatrics (Basel, Switzerland) · 2022Article
- Nonmetastatic Castration-Resistant Prostate Cancer: Current Challenges and Trends.Clinical drug investigation · 2022Review
- Real-World Use of Bone-Modifying Agents in Metastatic Castration-Sensitive Prostate Cancer.Journal of the National Cancer Institute · 2022Article
- Review
- Risk factors of skeletal-related events in patients with bone metastatic castration-resistant prostate cancer undergoing treatment with zoledronate.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2022Article
- Factors Affecting the Quality of Life of Patients with Painful Spinal Bone Metastases.Healthcare (Basel, Switzerland) · 2021Article
- Real-world safety and effectiveness of radium-223 in Japanese patients with castration-resistant prostate cancer (CRPC) and bone metastasis: exploratory analysis, based on the results of post-marketing surveillance, according to prior chemotherapy status and in patients without concomitant use of second-generation androgen-receptor axis-targeted agents.International journal of clinical oncology · 2021Article
- Costs and Healthcare Resource Utilization Associated with Hospital Admissions of Patients with Metastatic or Nonmetastatic Prostate Cancer.American health & drug benefits · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeUp to 75% of patients with prostate cancer experience metastatic bone disease, which leads to an increased risk for skeletal-related events (SREs) including pathological bone fracture, spinal cord compression, and hypercalcemia of malignancy. Our objective was to systematically review the literature on the impact of SREs on quality of life (QOL), morbidity, and survival with a primary focus on the impact of SREs on pain in prostate cancer patients.
methodsWe searched PubMed, limiting to peer-reviewed English-language human studies published in 2000-2010. The search was based on the US Food and Drug Administration and European Medicines Agency definition of an SRE, which includes pathologic fracture, spinal cord compression (SCC), hypercalcemia of malignancy, and radiotherapy or surgery to bone resulting from severe bone pain.
resultsA total of 209 articles were screened, of which 173 were excluded, and 36 were included in this review. Patients with SREs had more pain and worse survival compared with no SREs. Pathologic bone fractures worsened QOL and were associated with shorter survival. Radiation therapy of SCC alleviated pain and improved morbidity. SCC was associated with decreases in patient survival. Radiation therapy and surgery to bone improved pain.
conclusionsSpecific SREs are associated with worse outcomes, including increased pain, poorer QOL, morbidity, and survival. Treatment of SREs is associated with improved pain, although there remains a need for more effective treatment of SREs in prostate cancer patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.